Industry contributors
Dry Eye Foundation is deeply grateful to the organizations who help make our work possible!
Bausch & Lomb
June 2024: dry eye disease awareness partner
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey.
Bausch Foundation LLC provided a generous charitable contribution to Dry Eye Foundation in June 2024. Dry Eye Foundation is partnering with Bausch & Lomb on dry eye disease awareness initiatives in keeping with our mission.
DMV Corp
June 2024: Awareness Partner, My Big Fat Scleral Lens
DMV Corp is the world’s leader in contact lens handling products. Dr. Patterson and our team at DMV Corporation strive to meet the growing demand of contact lens handling products by constantly reevaluating DMV’s current product line and the need for developing new products, as well as expanding DMV products further around the world. We at DMV Corporation pride ourselves in continuing the tradition set by our founders and we pledge to continue that tradition into the future.
DMV Corp and Dry Eye Foundation are partnering on raising awareness about the MBFSL patient safety & education initiative.
Dalsey Adaptives
May 2024 - April 2025: Education Partner, My Big Fat Scleral Lens
Dalsey Adaptives has served the optometry profession and scleral lens patients for over 15 years with personalized customer service. Developed with patients, doctors, clinics and professional societies, our innovative patented See-Green System, Light and Stand® has changed the lives of thousands of users who struggled with lens insertion. Our products enable doctors to reduce training time and offer scleral lens options to a broader spectrum of patients.
Dalsey Adaptives and Dry Eye Foundation are partnering on scleral lens application education projects.
Sight Sciences
May 2024 - April 2025: Sponsor, Dry Eye Helpline
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. The company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
Scope Ophthalmics
July 2023 - June 2024: Sponsor, Dry Eye Helpline
Our family has been working within the healthcare sector in Ireland & UK for over 80 years. With this heritage Scope was founded by John and Tom Freyne in 2009.
Scope offers innovative management products for Ocular Surface Disease and Age-Related Macular Degeneration, as well as a well-established food supplement range.
Scope operates in the UK, Ireland, and the USA with a product offering with a track record of successfully helping patients worldwide.
Oyster Point
August 2023 - Charitable contribution, Dry Eye Helpline
We are a biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies to treat ophthalmic disease. We continuously strive to advance breakthrough science and deliver therapies to address the unmet needs of patients and professionals.
Oyster Point, which is now part of Viatris, owns Tyrvaya (varenicline solution) Nasal Spray for dry eye disease.
Tarsus Pharmaceuticals
July 2023 - Charitable contribution
Tarsus is a biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address highly prevalent diseases with limited treatment options. Serving patient needs is our passion; delivering revolutionary treatments is our mission.
We are a company that strives to embody the values of commitment, empowerment, and teamwork.
Tarsus’ treatment for Demodex blepharitis (Xdemvy - Lotilaner solution) was approved in July 2023.